23.20SEK-0.43%Mkt Cap: 2.21B SEKP/E: —Last update: 2026-06-01
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.21B SEK
Enterprise Value1.63B SEK
Revenue (TTM)1.80M SEK
Gross Profit-19.40M SEK
Net Income (TTM)-756.90M SEK
Revenue/Share0.0200 SEK
Last Price23.20 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0022447348
Valuation
P/E (Trailing)—
P/E (Forward)-56.83
PEG—
EV/EBITDA-47.88
EV/Revenue907.15
P/S1231.15
P/B0.60
EPS (TTM)-6.36
EPS (Forward)-0.41
52W Range
23.001% of range41.74
52W High41.74 SEK
52W Low23.00 SEK
Profitability
Gross Margin0.00%
Oper. Margin-11800.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.41%
ROA-22.28%
Growth
Revenue Growth-87.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.10M SEK
CapEx (TTM)—
FCF Margin621.56%
FCF Yield0.51%
Net Debt-583.20M SEK
Net Debt/EBITDA17.10
Balance Sheet
Debt/Equity0.00
Current Ratio100.41
Quick Ratio76.92
Book Value/Sh38.59 SEK
Cash/Share6.152 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split8:7
Split DateMay 15, 2026
Analyst Consensus
Rating—
Target (Mean)39.38 SEK
Target Range39.38 SEK – 39.38 SEK
# Analysts1
Ownership
Shares Out.95.11M
Float23.62M
Insiders90.62%
Institutions11.85%
Technical
SMA 5026.19 (-11.4%)
SMA 20032.10 (-27.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)41.22K
Avg Vol (10d)54.15K
Technical Indicators
RSI (14)36.9
MACD-0.5530
MACD Signal-0.6089
MACD Hist.+0.0559
BB Upper24.84 SEK
BB Middle23.96 SEK
BB Lower23.07 SEK
BB Width7.38%
ATR (14)0.6747 SEK
Vol Ratio (20d)0.16x